Puma rises on neratinib survival data, NDA submission

Puma Biotechnology Inc. (NYSE:PBYI) jumped $7 (20%) to $41.52 on Friday after the company disclosed interim five-year disease-free survival (DFS) data from the Phase III ExteNET trial of oral neratinib (PB272) and said it had submitted

Read the full 366 word article

User Sign In